Factors Affecting Graft Survival among Patients Receiving Kidneys from Live Donors: A Single-Center Experience

Table 4

Cox proportional hazard analysis.

Characteristic	Regression estimate; (B)	S.E.	Relative risk; Exp(B) (95% CI)	P value
Donor’s age (years)
<30	—	—	1
31–40	−0.049	0.097	0.952 (0.788, 1.150)	0.609
41–50	0.326	0.109	1.385 (1.120, 1.714)	0.003
>50	0.487	0.145	1.628 (1.224, 2.164)	<0.001
Genetic considerations
(i) HLA-ID siblings	—	—	1
(ii) 1-haplotype MM (R)	0.059	0.203	1.099 (0.739, 1.635)	0.641
(iii) 2-haplotype MM (R + UR)	0.404	0.211	1.498 (0.990, 2.267)	0.056
No. of acute rejection episodes (during first 3 months)
(i) No	—	—	1
(ii) One	0.779	0.130	2.218 (1.689, 2.814)	<0.001
(iii) ≥2	1.559	0.131	4.754 (3.737, 6.141)	<0.001
Total steroid dose (during first 3 months)
<5 gm	—	—	1
5–10 gm	−0.363	0.100	0.696 (0.572, 0.846)	0.001
>10 gm	−0.294	0.135	0.745 (0.572, 0.972)	0.030
Primary immunosuppression
(i) Aza-based (dual therapy)	—	—	1
(ii) CsA-based (dual therapy)	−0.022	0.139	0.978 (0.744, 1.285)	0.872
(iii) CsA-based (triple therapy)	−0.234	0.114	0.791 (0.633, 0.989)	0.039
(iv) Tacrolimus-based (triple therapy)	−0.686	0.228	0.504 (0.322, 0.787)	0.003